Evidence map›Paper›PMID 32287168›Full record

ArticleJournal of infusion nursing : the official publication of the Infusion Nurses Society

Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy.

William Lumry, Teri Templeton, Laurel Omert, Donald Levy

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of infusion nursing : the official publication of the Infusion Nurses Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

William LumryAARA Research Center, Dallas, Texas (Dr Lumry); US HAEA Angioedema Center at University of California San Diego, San Diego, California (Ms Templeton); CSL Behring, King of Prussia, Pennsylvania (Dr Omert); University of California Irvine School of Medicine, Orange, California (Dr Levy).
Teri TempletonAARA Research Center, Dallas, Texas (Dr Lumry); US HAEA Angioedema Center at University of California San Diego, San Diego, California (Ms Templeton); CSL Behring, King of Prussia, Pennsylvania (Dr Omert); University of California Irvine School of Medicine, Orange, California (Dr Levy).
Laurel OmertAARA Research Center, Dallas, Texas (Dr Lumry); US HAEA Angioedema Center at University of California San Diego, San Diego, California (Ms Templeton); CSL Behring, King of Prussia, Pennsylvania (Dr Omert); University of California Irvine School of Medicine, Orange, California (Dr Levy).
Donald LevyAARA Research Center, Dallas, Texas (Dr Lumry); US HAEA Angioedema Center at University of California San Diego, San Diego, California (Ms Templeton); CSL Behring, King of Prussia, Pennsylvania (Dr Omert); University of California Irvine School of Medicine, Orange, California (Dr Levy).
Parkland Memorial Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary angioedema (HAE) is a debilitating condition caused by a functional C1-inhibitor (C1-INH) deficiency and characterized clinically by episodes of subcutaneous or submucosal swelling. C1-INH replacement is highly effective for preventing HAE attacks and can improve health-related quality of life. Once available only for intravenous use, C1-INH is now available as a subcutaneous formulation for self-administration, shown to provide sustained plasma levels of C1-INH and reducing the monthly median HAE attack rate by 95% versus placebo in the phase 3 COMPACT study. Subcutaneously administered C1-INH satisfies multiple unmet needs in the management of patients with HAE.

Indexed as

Clinical Trials as TopicInjections, SubcutaneousPractice Guidelines as TopicSelf AdministrationAngioedemas, HereditaryComplement C1 Inhibitor ProteinHumansComplement C1 Inhibitor Protein

Identifiers

PMID32287168
PMCPMC7328861
OpenAlexW3016021524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.